Minglan Shijia Secures Seed Funding from YuanYi Capital to Advance Digital Integrated Solutions for Cervical Intraepithelial Neoplasia

VCBeat has learned that Minglan Shijia (Beijing) Medical Technology Co., Ltd. (“Minglan Shijia”) has announced the completion of a seed funding round exclusively invested by Yuanyi Capital. The funds raised will be used for the research and development of the company’s integrated digital solutions for the screening, diagnosis, and treatment of cervical epithelial lesions.

Founded in November 2022, Minglan Shijia focuses on women’s health across the entire reproductive lifecycle and specializes in digital therapeutics for obstetrics and gynecology. Leveraging advanced AI algorithms, a precise clinical perspective, and robust user operation capabilities, the company has developed a patient-centered AI-assisted diagnostic report interpretation system for cervical cancer screening, based on real-world data. This solution provides precise empowerment for the integrated pathway of cervical cancer screening, diagnosis, and treatment.

The company’s founder, Du Xinxin, has led the team to win numerous honors, including the “Chunhui Cup” at the Chinese Overseas Scholars Innovation and Entrepreneurship Competition organized by the Ministry of Education of China, Third Prize in the Jiangsu Province “Ningju” International Project Cross-border Roadshow Competition, and Third Prize in the Jinan City, Shandong Province New Momentum International High-Level Talent Innovation and Entrepreneurship Competition.

Cervical cancer is one of the common malignant tumors in gynecology. Its development process usually progresses from normal epithelium to cervical intraepithelial neoplasia, and then to invasive cervical cancer.

Cervical epithelial lesions are precancerous conditions associated with cervical cancer; therefore, the screening, diagnosis, and treatment of these lesions hold significant clinical importance for the prevention and control of cervical cancer.

Minglan Shijia has developed an integrated digital solution for physicians and patients, focusing on cervical epithelial lesions. Built upon its proprietary large-scale medical AI model for health analysis and reasoning, and combined with advanced artificial intelligence algorithms, the product provides a comprehensive digital service encompassing screening, diagnosis, and treatment of cervical epithelial lesions. This innovation enhances diagnostic and therapeutic efficiency for clinicians, improves the healthcare experience for patients, and supports the widespread prevention and control of cervical cancer.

For this round of financing,Du Xinxin, Founder of Minglan Shijia“The company stated: ‘We extend our heartfelt gratitude to Yuan Yi Capital for its trust and support in Minglan Shijia. It is our privilege to have earned the favor of Yuan Yi Capital, which has injected powerful momentum into our pursuit of our mission and goals. We will fully leverage the advantages of this partnership to accelerate innovation and development. Minglan Shijia recognizes that women’s health is crucial to the sound development of society as a whole. We will remain steadfast in our principles of “professionalism, innovation, and integrity,” continuously exploring and applying advanced technological solutions. Working together with Yuan Yi Capital, we are committed to making positive contributions to the cause of women’s health and to the sustainable development of society.’”

Yuan Yi Capital“It was founded by a leading domestic expert team in the field of cervical cancer. Starting with patient management for cervical cancer screening, it extends to women’s health management, leveraging AI-powered products to enhance convenience and accuracy, improve screening efficiency, and create value for payers, hospitals, and patients.””

Yuan Yi Capital, established in 2016, is an early-stage venture capital fund focused on the digital health technology sector. Currently, the cumulative assets under management (AUM) of its multiple RMB and USD funds exceed the equivalent of RMB 3 billion.

Yuan Yi Capital focuses on early-stage investment opportunities in digital health, making forward-looking investments in three key infrastructure areas: efficient access, innovative payment models, and operational efficiency enhancement. These efforts help facilitate the transformation and upgrading of healthcare systems in China and globally, driving cost reduction, efficiency improvement, quality enhancement, and cost control. To date, Yuan Yi Capital has invested in nearly one hundred high-quality innovative companies across various digital health sectors, including medical devices and equipment with core technologies and innovative business models, mobile health and services, precision diagnostics, and health insurance technology.